Fed. Circ. Backs Genentech's Win On Phigenix Cancer Patent
The Federal Circuit on Thursday upheld a victory for Genentech Inc. over its breast cancer drug Kadcyla, finding that the district judge was not wrong to exclude Phigenix Inc.'s expert report...To view the full article, register now.
Already a subscriber? Click here to view full article